Information  X 
Enter a valid email address

Veos PLC (VEO)

  Print      Mail a friend

Wednesday 17 July, 2002

Veos PLC

Directorate Change

Veos PLC
17 July 2002



                         Veos plc ('Veos' or 'the Company')

                            Appointment of New Directors

Further to the announcement dated 27th June 2002, in which it was stated that
the composition of the new Board of Directors would be announced shortly, Veos
today announced the appointment of four new directors with effect from 1st
August 2002. They are: William Pfister, Erica L. Gollub, Nigel McWilliam, and
Michael Widmer. The Company also confirmed that Paul Lewakowski, currently
president of Veos USA Inc. has agreed to become the Company's interim Chief
Executive Officer, joining the Board on the same date.


William Pfister, Ph.D. (age 51) is Senior Director Preclinical Affairs at NexMed
(U.S.A.), Iocated in Robbinsville, New Jersey, where he is responsible for
preclinical safety testing for all research and development activities. Dr.
Pfister has over 20 years of experience in the areas of Pharmaceutical Research
and Development, Technical Services, Regulatory Affairs, Quality Assurance,
Quality Control, Preclinical Safety Testing and Project Management. He has held
management positions at Lavipharm Laboratories Inc., Pharmetrix Division of
TCPI, Pharma Patch PLC, Pharmetrix, Dow Corning Corporation, formerly American
Critical Care, now Du Pont Pharmaceuticals and Hoffmann-La Roche. Dr. Pfister
has published and presented over 95 scientific papers in the areas of
Pharmacology, Toxicology, Controlled Drug Delivery, Pressure Sensitive
Adhesives, and Transdermal Drug Delivery Systems. Dr. Pfister holds a B.S.
degree in Biochemistry from the University of New Hampshire, a M.S. and Ph.D.
degree in Pharmacology and Toxicology from Purdue University School of Pharmacy
and Pharmacal Sciences and is a Diplomat of the American Board of Toxicology
(DABT), holds a California Board of Pharmacy Exemptee License for the
manufacture of drugs and is a Certified Regulatory Affairs Professional (RAC).
Dr. Pfister has focused his interests over the past 15 years in the Research and
Development of controlled drug delivery systems and their components including
pressure sensitive adhesives, permeation enhancers, and the design and
formulation of transdermal and transmucosal dosage forms and patches for
non-invasive in vitro diagnostic applications. He has been responsible for the
clinical development and regulatory filings to obtain product approvals. He has
been a member of Veos' Scientific Advisory Board since 1999.


Erica L. Gollub, DrPH (age 45) is Research Assistant Professor of Epidemiology
in Psychiatry at the Center for Addiction Studies, at the University of
Pennsylvania in Philadelphia. Her current research focuses on women and HIV/AIDS
prevention. Dr. Gollub has presented widely on her research, including invited
presentations at the World AIDS Conference and at the World Health Organization,
where she has served as a consultant. Dr. Gollub received her BS from Stanford
University and her MPH (in Population and Family Health) and DrPH (Epidemiology)
from Columbia University, where her dissertation was on the feasibility and
effectiveness of public health screening for ovarian cancer. An international
expert on women's barrier contraception and disease prevention, she has two
decades' of clinical experience with the cervical cap and other barrier
contraception, and has often testified at FDA hearings, and served on NIH
advisory boards, since the early 1980s, regarding regulation of barrier
contraception and the future of contraceptive research. In 1986, she established
a women's informational and health service regarding cervical caps, in New York
City (Womancap). She has published widely on issues of reproductive health and
women. Dr Gollub has been the Chairman of the Company's Scientific Advisory
Board since March 2001.


Nigel McWilliam (age 51) is currently US Senior Vice President (Business
Development) for SkyePharma, where his activities include implementing
SkyePharma's dual strategy of developing products based upon its own technology,
and also providing these platforms to client funded developments, to a global
pharmaceutical audience, in the USA and throughout Asia. Prior to joining
SkyePharma, Mr. McWilliam was employed for almost 20 years by Dow Corning
Corporation in Europe and the USA, developing, marketing and licensing
functional excipients for drug delivery by various routes of administration.
Since graduating from the University of Dundee, Scotland in 1973, his career has
been exclusively in the health care field. Mr McWilliam was a director of Veos
Limited until February 1999.


Michael Widmer (age 34) is currently Vice President Private Banking for Deutsche
Bank in Zurich, Switzerland. He has an extensive background in the financial
services industry and over 10 years of management experience. He has been
employed by companies including Credit Suisse, American International and
Citigroup. He has an extensive network of contacts in the private equity scene
in Europe. Mr. Widmer has a degree in economics from KVZ in Zurich.


Paul Lewakowski (age 39) has been the President of Veos USA Inc for the past 5
years. Mr Lewakowski was appointed as a non-executive director of Veos Limited
in May 1996, becoming an employee of that company in March 1997. In 1987, he
suffered a personal bankruptcy from which he has since been fully discharged.
This was the result of uninsured US medical costs for his first child and was
not related to the management of a business. Mr Lewakowski was the co-founder of
the Veos group of companies. Prior to this, he was a Vice-President of Paine
Webber, Inc. from 1994 to 1997, where he was responsible for managing funds for
some 450 individuals and corporate customers. Mr Lewakowski has been responsible
for raising development capital for Veos. He was physics major at Illinois State
University.

There are no further disclosures to be made regarding any of the new directors
in respect of Schedule 2 (f) (iii)-(viii) of the AIM Rules.

Commenting on the new appointments, Paul Lever, Chairman of Veos, stated, 'We
are excited about the addition of these new directors to Veos plc. Being able to
attract directors of this calibre to Veos will position the Company to proceed
aggressively with its business and financial strategies.'


About Veos

Veos is a female healthcare company. The Company's main business is the
marketing of its Oves female barrier contraceptive product in the United
Kingdom, principally through a distribution agreement with the UK retailer,
Boots The Chemist. Veos is currently planning Phase III FDA trials for the Oves
contraceptive product in the United States and is in the development phase with
a drug-loaded device to combat sexually transmitted disease. Veos has also
received FDA approval for its conception product in the US. Veos has a number of
patents and its long-term objectives are for the Company to offer an innovative
range of female reproductive healthcare products.


For additional information, contact:


Paul Lewakowski

Veos plc 001-847-735-0003


Paul Lever

Chairman - Veos plc +44 (0)20 7960 6066


Jeffrey Friedland

Friedland Capital Inc. 001-303-282-5767




                      This information is provided by RNS
            The company news service from the London Stock Exchange
                                                                     

a d v e r t i s e m e n t